|
|
CD56阳性与IGG型多发性骨髓瘤的相关性
|
Abstract:
目的：探讨CD56阳性表达与IGG型多发性骨髓瘤的相关性。方法：从浙江大学医学院附属邵逸夫医院历史性队列中选择2017年1月至2020年12月进行初次治疗的62例IGG型多发性骨髓瘤患者。流式细胞术检测患者治疗前骨髓恶性浆细胞的免疫标记表达情况，将患者分为CD56阳性组和CD56阴性组。分析CD56表达在IGG型多发性骨髓瘤分型中的临床应用。结果：62例MM患者恶性浆细胞CD56表达与浆细胞比例无显著相关(P > 0.05)，但与其年龄大小、DS分期、血色素有显著相关(P < 0.05)，而且，CD56表达为阳性时，具有的特点是：年龄小、DS分期早、血色素高。这些都是MM预后的保护因素。结论：CD56阳性表达与IGG型多发性骨髓瘤具有一定相关性。
Objective: To investigate the correlation between CD56 positive expression and IGG multiple mye-loma. Methods: A total of 62 patients with IGG multiple myeloma who underwent initial treatment from January 2017 to December 2020 were selected from the historic cohort of Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine. Flow cytometry detected the im-munomarked expression of malignant plasma cells in the bone marrow before treatment and the patients were divided into CD56-positive and CD56-negative groups. Analyze the clinical application of CD56 expression in the typing of IGG-type multiple myeloma. Results: In 62 patients with MM, there was no significant correlation between CD56 expression and plasma cell proportion (P > 0.05), but it is significantly correlated with their age, DS staging and hemoglobin (P < 0.05), and when CD56 is expressed positively, it is characterized by small age, early DS staging, and high hemoglobin. These are all protective factors for MM prognosis. Conclusions: There is a certain correlation be-tween CD56 positive expression and IGG-type multiple myeloma.
| [1] | McCullough, K.B., Hobbs, M.A., Abeykoon, J.P., et al. (2018) Common Adverse Effects of Novel Therapies for Multi-ple Myeloma (MM) and Their Management Strategies. Current Hematologic Malignancy Reports, 13, 114-124.
https://doi.org/10.1007/s11899-018-0443-0 |
| [2] | Paiva, B., Almeida, J., Perez-Andres, M., et al. (2010) Utility of Flow Cytometry Immunophenotyping in Multiple Myeloma and Other Clonal Plasma Cell-Related Disorders. Cytometry Part B: Clinical Cytometry, 78, 239-252.
https://doi.org/10.1002/cyto.b.20512 |
| [3] | Bataille, R., Pellat-Deceunynck, C., Robillard, N., et al. (2008) CD117 (c-kit) Is Aberrantly Expressed in a Subset of MGUS and Multiple Myeloma with Unexpectedly Good Prognosis. Leu-kemia Research, 32, 379-382.
https://doi.org/10.1016/j.leukres.2007.07.016 |
| [4] | 中国医师协会血液科医生分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订) [J]. 中华内科杂志, 2020, 59(5): 341-346. |
| [5] | Raja, K.R., Kovarova, L. and Hajek, R. (2010) Review of Phenotypic Markers Used in Flow Cytometric Analysis of MGUS and MM, and Applicability of Flow Cytometry in Other Plasma Cell Disorders. British Journal of Haematology, 149, 334-351. https://doi.org/10.1111/j.1365-2141.2010.08121.x |
| [6] | Schouweiler, K.E., Karandi-kar, N.J. and Holman, C.J. (2019) Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Mye-loma Minimal Residual Disease Detection by Multiparameter Flow Cytometry. Cytometry Part B: Clinical Cytometry, 96, 310-318. https://doi.org/10.1002/cyto.b.21789 |
| [7] | 王星, 张瑜, 马列婷. 流式细胞术免疫分型对多发性骨髓瘤的诊断价值[J]. 中国卫生标准管理, 2019, 10(18):131-134. |
| [8] | Pan, Y., Wang, H., Tao, Q., et al. (2016) Absence of Both CD56 and CD117 Expression on Malignant Plasma Cells Is Related with a Poor Prognosis in Patients with Newly Diagnosed Multiple Myeloma. Leukemia Research, 40, 77-82.
https://doi.org/10.1016/j.leukres.2015.11.003 |
